Journal
PLOS ONE
Volume 9, Issue 12, Pages -Publisher
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0113328
Keywords
-
Categories
Funding
- AstraZeneca
- Australian Research Council Future Fellowship
Ask authors/readers for more resources
The current study extends previously reported PPAR alpha agonist WY 14,643 (30 mmol/kg/day for 4 weeks) effects on circulating amino acid concentrations in rats fed a 48% saturated fat diet. Steady-state tracer experiments were used to examine in vivo kinetic mechanisms underlying altered plasma serine, glycine and arginine levels. Urinary urea and creatinine excretion were measured to assess whole-body amino acid catabolism. WY 14,643 treated animals demonstrated reduced efficiency to convert food consumed to body weight gain while liver weight was increased compared to controls. WY 14,643 raised total amino acid concentration (38%), largely explained by glycine, serine and threonine increases. H-3-glycine, C-14-serine and C-14-arginine tracer studies revealed elevated rates of appearance (R-a) for glycine (45.5 +/- 5.8 versus 17.4 +/- 2.7 mu mol/kg/min) and serine (21.0 +/- 1.4 versus 12.0 +/- 1.0) in WY 14,643 versus control. Arginine was substantially decreased (-62%) in plasma with estimated R-a reduced from 3.1 +/- 0.3 to 1.2 +/- 0.2 mu mol/kg/min in control versus WY 14,643. Nitrogen excretion over 24 hours was unaltered. Hepatic arginase activity was substantially decreased by WY 14,643 treatment. In conclusion, PPAR alpha agonism potently alters metabolism of several specific amino acids in the rat. The changes in circulating levels of serine, glycine and arginine reflected altered fluxes into the plasma rather than changes in clearance or catabolism. This suggests that PPAR alpha has an important role in modulating serine, glycine and arginine de novo synthesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available